Does Highmark Cover Eliquis? A Complete Insurance and Clinical Guide

How Highmark Formularies Work and Where Eliquis Fits

Highmark Blue Cross Blue Shield operates dozens of distinct plan designs across Pennsylvania, Delaware, West Virginia, and New York. Each plan publishes its own formulary, which is a ranked list of covered drugs organized by tier. Tier placement determines how much you pay at the pharmacy.

Eliquis sits on Tier 3 (preferred brand) in the majority of Highmark commercial formularies reviewed for 2024 and 2025 plan years. A minority of Medicare Advantage and ACA exchange plans place it on Tier 4 (non-preferred brand), which carries a higher copay or coinsurance.

Tier Definitions on a Typical Highmark Plan

• Tier 1: Generic drugs, lowest cost share (often $5, $15)
• Tier 2: Preferred generics or select low-cost brands ($20, $40)
• Tier 3: Preferred brand-name drugs ($47, $100 copay per 30-day supply on most Highmark commercial plans)
• Tier 4: Non-preferred brands ($80, $150 or 25 to 40% coinsurance)
• Tier 5: Specialty drugs (percentage-based, often 25 to 33%)

Because no FDA-approved generic apixaban existed as of mid-2025, Eliquis cannot be substituted at the pharmacy counter the way a generic statin can. This keeps it in the brand-name tiers.

Checking Your Specific Plan

The most reliable method is to log into your Highmark member portal and use the Drug Cost Tool, then enter "apixaban" or "Eliquis." You can also call the Member Services number on the back of your insurance card. The FDA's drug information page for apixaban confirms the approved formulations, which your plan's formulary manager uses to classify coverage.

Prior Authorization: What Highmark Requires for Eliquis

Most Highmark plans require prior authorization (PA) before they will pay for Eliquis. PA is a formal review process in which your prescriber submits clinical documentation proving the drug is medically necessary for your condition.

Highmark's PA criteria for Eliquis typically mirror the FDA-approved label indications. Prescribers must usually document one of the following: nonvalvular atrial fibrillation (AFib) with a CHA2DS2-VASc score of 2 or higher in men (3 or higher in women), an acute DVT or PE diagnosis, post-surgical VTE prophylaxis following hip or knee replacement, or prevention of recurrent DVT/PE.

Documents Your Doctor Will Need to Submit

1. Diagnosis code (ICD-10): I48.x for AFib, I82.x for DVT, I26.x for PE
2. CHA2DS2-VASc score calculation for AFib indications
3. Documentation that warfarin was considered or trialed, or a clinical rationale for starting a direct oral anticoagulant (DOAC) first
4. Relevant lab values (creatinine, weight, age for dose-reduction criteria)

The 2023 ACC/AHA/ACCP/HRS Guideline for Diagnosis and Management of Atrial Fibrillation gives a Class I, Level A recommendation for DOACs over warfarin in eligible AFib patients. Highmark's medical policies generally align with that guideline language.

Timeline and What Happens If PA Is Denied

Standard PA decisions take up to 72 hours for non-urgent requests; urgent requests must be answered within 24 hours under Pennsylvania insurance regulations. If denied, your physician can request a peer-to-peer review with Highmark's medical director within 5 business days. You may also file a Level 1 internal appeal within 60 days of the denial notice, followed by a Level 2 external appeal if the Level 1 is upheld.

Clinical Evidence Supporting Eliquis (Apixaban)

Understanding why a prescriber chooses Eliquis, not warfarin or another DOAC, matters because Highmark's PA reviewers weigh that clinical rationale directly. The evidence base for apixaban is extensive.

ARISTOTLE Trial: AFib Stroke Prevention

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily to warfarin in patients with nonvalvular AFib. Apixaban reduced the rate of stroke or systemic embolism by 21% (1.27% vs. 1.60% per year; P<0.001), reduced major bleeding by 31% (2.13% vs. 3.09% per year; P<0.001), and reduced all-cause mortality by 11% (P=0.047) [1]. These results, published in the New England Journal of Medicine, form the cornerstone of every major guideline recommendation for apixaban in AFib.

The ARISTOTLE publication in NEJM is the single most-cited trial in Highmark's coverage rationale documentation for this drug class.

AMPLIFY Trial: DVT and PE Treatment

In the AMPLIFY trial (N=5,395), apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily was compared to conventional therapy (enoxaparin bridging to warfarin) for acute VTE [2]. Apixaban was non-inferior for the primary efficacy outcome (recurrent VTE or VTE-related death: 2.3% vs. 2.7%; relative risk 0.84; 95% CI 0.60 to 1.18) and produced 69% less major bleeding (0.6% vs. 1.8%; P<0.001). The AMPLIFY trial is indexed on PubMed.

ADVANCE Trials: Post-Surgical VTE Prophylaxis

The ADVANCE-2 and ADVANCE-3 trials studied apixaban 2.5 mg twice daily vs. Enoxaparin after knee and hip replacement surgery. ADVANCE-3 (N=5,407) showed apixaban reduced the composite of VTE and all-cause mortality by 64% compared to enoxaparin after hip replacement (1.4% vs. 3.9%; P<0.001) with similar major bleeding rates [3]. PubMed records for ADVANCE-3 are available here.

Why Apixaban Over Other DOACs?

Rivaroxaban, dabigatran, and edoxaban are all formulary alternatives Highmark may prefer on some plans. Apixaban differs from rivaroxaban in one mechanistically important way: it is dosed twice daily, which produces more stable plasma drug levels. A 2022 network meta-analysis published in The BMJ (N=47 trials, 283,000 patients) found apixaban had the most favorable bleeding profile of the four approved DOACs while maintaining comparable efficacy for stroke prevention in AFib [4]. The BMJ network meta-analysis is accessible here.

How Much Does Eliquis Cost With Highmark?

Cost depends on three variables: your plan's tier placement for Eliquis, whether you have met your deductible, and which pharmacy you use.

Typical Cost Scenarios

| Plan Type | Tier | Monthly Copay (30-day supply) | |---|---|---| | Highmark commercial (Tier 3) | Preferred brand | $47, $100 | | Highmark BCBS Medicare Advantage | Tier 3 or 4 | $47, $150 | | ACA exchange silver plan | Tier 4 | $80, $175 | | No insurance or deductible phase | N/A | $480, $560 |

These figures reflect pharmacy benefit structures typical of Highmark plans for 2024 to 2025. Your Explanation of Benefits (EOB) will show your exact cost share.

Eliquis 360 Support Program

Bristol-Myers Squibb and Pfizer jointly run the Eliquis 360 Support program. Commercially insured patients with an out-of-pocket cost above $10/month may qualify for a copay card reducing their cost to as low as $10 for a 30-day supply. Medicare and Medicaid beneficiaries do not qualify for the copay card but may qualify for the patient assistance program, which provides free drug to those meeting income criteria (generally household income at or below 400% of the federal poverty level). Details are at 1-855-ELIQUIS or through the prescriber's office.

The FDA's patient assistance guidance points patients toward manufacturer programs when insurance coverage is insufficient.

Alternatives Highmark May Prefer on Some Plans

If Eliquis is not covered on your specific plan or carries an unaffordable copay, other anticoagulant options exist. Your prescriber must weigh clinical suitability first.

Other DOACs on Highmark Formularies

Rivaroxaban (Xarelto): Approved for the same AFib, DVT, and PE indications. Some Highmark plans place rivaroxaban on a lower tier than apixaban, making it cheaper before switching. The ROCKET-AF trial (N=14,264) showed rivaroxaban non-inferior to warfarin for AFib stroke prevention, though with a higher gastrointestinal bleeding rate than apixaban in head-to-head network analyses [4].

Warfarin (Coumadin): Available as a generic, often Tier 1 on all Highmark plans. Requires regular INR monitoring and has numerous food and drug interactions. The ACC/AHA 2023 AFib guideline reserves warfarin primarily for patients with mechanical heart valves or significant renal impairment where DOACs are contraindicated.

Dabigatran (Pradaxa): A direct thrombin inhibitor rather than a Factor Xa inhibitor. The RE-LY trial (N=18,113) showed dabigatran 150 mg twice daily superior to warfarin for stroke prevention but with higher gastrointestinal bleeding rates. Highmark tier placement varies by plan year.

When Switching Requires a Formulary Exception

If your prescriber determines that the formulary alternative is clinically inappropriate for you (for example, because you have a history of gastrointestinal bleeding that makes rivaroxaban a worse choice, or renal impairment that affects dabigatran clearance), they can submit a formulary exception request citing clinical necessity. Highmark must process exception requests within the same PA timelines: 72 hours standard, 24 hours urgent.

Dose-Reduction Criteria: Getting the Right Coverage for the Right Dose

Highmark may specifically authorize a dose. The FDA-approved dose-reduction criteria for apixaban in AFib are defined by the package insert: patients receive 2.5 mg twice daily instead of 5 mg twice daily if they meet at least two of the following three criteria: age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher [5]. Prescribing the standard 5 mg dose when dose reduction is indicated may trigger a PA denial or pharmacist clarification call.

The FDA prescribing information for Eliquis provides the complete dose table. Submitting this document reference number with the PA request can accelerate review.

For DVT and PE treatment, the FDA-approved regimen is 10 mg twice daily for the first 7 days, then 5 mg twice daily. For extended prevention of recurrent DVT/PE after at least 6 months of treatment, the dose drops to 2.5 mg twice daily. Each phase may need separate authorization if Highmark's system tracks duration-based approvals, which some commercial plans do.

What to Do if Highmark Denies Eliquis Coverage

A denial is not a final answer. The process has multiple escalation steps, each with defined timelines under federal and Pennsylvania state law.

Step-by-Step Appeal Process

1. Request a peer-to-peer review. Your prescribing physician calls Highmark's clinical review line within 5 business days. Many PA denials are reversed at this stage when the physician can speak directly with the reviewing clinician.

2. File a Level 1 internal appeal. Submit within 60 days of the denial notice. Include the ARISTOTLE trial citation [1], your physician's clinical letter, and any specialist notes. Highmark must respond within 30 days for standard appeals, 72 hours for urgent ones.

3. Request an external independent review. If the Level 1 appeal fails, you have the right to an external review by an independent organization under the Affordable Care Act. Pennsylvania's Insurance Department oversees this process.

4. Contact Pennsylvania's Insurance Department. File a complaint at 1-800-882-9900 if you believe the denial violates your plan's terms or Pennsylvania insurance law.

5. Explore bridge therapy. While appealing, ask your physician whether short-term bridging with low-molecular-weight heparin (enoxaparin) is appropriate and covered while the appeal resolves.

The FDA's guidance on drug approvals does not govern insurance decisions, but citing the approved indication explicitly in appeal letters strengthens the medical necessity argument.

Drug Interactions and Safety Considerations That Affect Coverage Documentation

Highmark's PA reviewers assess not just the diagnosis but also the safety profile. Documenting drug interactions in the PA request can preempt a denial.

Major Interactions

Apixaban is metabolized by CYP3A4 and is a P-glycoprotein (P-gp) substrate. Strong dual inhibitors of CYP3A4 and P-gp (such as ketoconazole, itraconazole, ritonavir, and clarithromycin) increase apixaban exposure and may require dose adjustment. Strong dual inducers (such as rifampin, carbamazepine, phenytoin, and St. John's Wort) reduce apixaban exposure by up to 54%, potentially making the standard dose insufficient [5].

The FDA Eliquis label specifies that the dose should be halved to 2.5 mg twice daily when patients on 5 mg twice daily also take strong dual CYP3A4/P-gp inhibitors, and that the combination should be avoided entirely in patients already on the 2.5 mg twice daily dose-reduction regimen.

Renal and Hepatic Impairment

Approximately 27% of apixaban is cleared renally. Patients with end-stage renal disease on dialysis present a special case: the 2021 ISTH guidance on anticoagulation in dialysis patients notes limited evidence but acknowledges clinical use of apixaban at 5 mg twice daily in dialysis patients, though labeling does not formally extend to this population. Highmark's medical necessity reviewers may require additional documentation for this off-label use.

Severe hepatic impairment (Child-Pugh Class C) is a contraindication per the FDA label [5]. Documenting normal hepatic function or mild impairment in the PA packet can prevent a denial based on this safety exclusion.

Monitoring and Long-Term Management

Unlike warfarin, apixaban does not require routine INR monitoring. This simplifies long-term management but removes the natural checkpoint that routine lab visits provide.

Clinicians prescribing apixaban for chronic AFib should reassess renal function at least annually, because creatinine changes may trigger the dose-reduction criteria described above. The 2023 AHA/ACC AFib guideline recommends reassessing stroke and bleeding risk scores annually using validated tools such as CHA2DS2-VASc and HAS-BLED.

The ORBIT-AF II registry (N=9,614 AFib patients) found that 15.3% of patients on DOACs were on incorrect doses at baseline, most commonly under-dosed rather than over-dosed, which was associated with worse clinical outcomes [6]. Highmark's utilization management programs flag dose discrepancies and may require prescriber confirmation before dispensing.

Patients should also be counseled that apixaban has no approved reversal agent in the way warfarin does with vitamin K. Andexanet alfa (Andexxa) provides Factor Xa inhibitor reversal and carries FDA approval, but its cost (often exceeding $25,000 per course) means Highmark requires separate authorization if it is ever needed in a bleeding emergency.

The FDA approval record for andexanet alfa confirms its indication for patients on rivaroxaban or apixaban with life-threatening or uncontrolled bleeding.